First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
University of Cologne · Integrated Oncology (United States) · +18 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
620
total citations
- FWCI
- 52.04
- Percentile
- 100%
- References
- 31
Citations per year
Authors
26- BEBarbara EichhorstCorresponding
University of Cologne, Integrated Oncology (United States), University Hospital Cologne
- AFAnna‐Maria Fink
University of Cologne, University Hospital Cologne
- JBJasmin Bahlo
University of Cologne, University Hospital Cologne
- RBRaymonde Busch
- GKGábor Kovács
University of Cologne, University Hospital Cologne
Topics & keywords
Topics
Keywords
- Chemoimmunotherapy
- Bendamustine
- Rituximab
- Fludarabine
- Medicine
- Ofatumumab
- Internal medicine
- Oncology
No related works found for this paper.